Biosimilars were first introduced into the US market about six years ago, but getting the all-important “patient buy-in” has been a slow process. Many patients are reluctant to switch to a biosimilar if they’re already happy taking a biologic. But another reason is the proliferation of myths and misinformation about biosimilars, which can be difficult to counteract.
In this episode, Zoe and Conner talk to a few medical professionals about the most common biosimilar falsehoods, and what can be done to stop their spread.
Among the highlights in this episode:
1:58 – The FDA begins cracking down on misinformation
2:47 – Myth #1: Patients confuse biosimilar drugs with generic drugs
3:06 – Doctors’ initial concerns about quality control
3:38 – Hesitancy about ‘transferability’
4:54 – Myth #2: Biosimilars won’t save money
5:50 – Myth #3: Biologics are natural monopolies
Contact Our Hosts:
Zoe Rothblatt, Patient Advocate and Community Outreach Manager at GHLF. zrothblatt@ghlf.org
Conner Mertens, Patient Advocate and Community Outreach Manager at GHLF. cmertens@ghlf.org
We’d love to hear what you think. Send your comments to BreakingDownBiosimilars@GHLF.org
See omnystudio.com/listener for privacy information.
